Biodistribution and imaging of FDG in rats with LS174T carcinoma xenografts and focal Escherichia coli infection
P. Kok, J. van Eerd, O. Boerman, F. Corstens and W. OyenArticles
CANBR
2005
310--315
Leukocytes in Complex Regional Pain Syndrome type I
E. Tan, W. Oyen and R. GorisArticles
Inflammation
2005
182--186
Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin
M. Koppe, R. Bleichrodt, A. Soede, A. Verhofstad, D. Goldenberg, W. Oyen and O. BoermanArticles
JNM
2004
1224--1232
Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re
A. Brouwers, J. van Eerd, C. Frielink, E. Oosterwijk, W. Oyen, F. Corstens and O. BoermanArticles
JNM
2004
327--337
[18F]Fluoro-2-deoxy-D-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier
M. van Kouwen, J. Drenth, W. Oyen, J. de Bruin, M. Ligtenberg, J. Bonenkamp, J. van Krieken and F. NagengastArticles
CLINCR
2004
6456--6459
FDG-PET scanning in the diagnosis of gastrointestinal cancers
M. van Kouwen, W. Oyen, F. Nagengast, J. Jansen and J. DrenthArticles
SCAJGAS
2004
85--92
[The biopsying of at least 5 mediastinal lymph node stations for presurgical staging in patients with a non-small-cell lung carcinoma]
A. Verhagen, E. Bollen, V. Tjan-Heijnen, G. Bootsma, A. Hensens and W. OyenArticles
NTVG
2004
908; author reply 908--908; author reply 909
FDG-PET in staging lung cancer: how does it change the algorithm?
A. Verhagen, G. Bootsma, V. Tjan-Heijnen, G. van der Wilt, A. Cox, M. Brouwer, F. Corstens and W. OyenArticles
LUNGC
2004
175--181
Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors
P. Laverman, M. Béhé, W. Oyen, P. Willems, F. Corstens, T. Behr and O. BoermanArticles
Bioconjug Chem
2004
561--568
PET/CT: panacea, redundancy, or something in between?
W. Vogel, W. Oyen, J. Barentsz, J. Kaanders and F. CorstensArticles
JNM
2004
15S--24S
Imaging of experimental colitis with a radiolabeled leukotriene B4 antagonist
J. van Eerd, P. Laverman, W. Oyen, T. Harris, D. Edwards, C. Ellars, F. Corstens and O. BoermanArticles
JNM
2004
89--93
Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases
B. Wiering, T. Ruers and W. OyenArticles
ERACT
2004
607--613
Tracers to monitor the response to chemotherapy: in vitro screening of four radiopharmaceuticals
L. de Geus-Oei, J. van Eerd-Vismale, C. Molthoff, F. Corstens, W. Oyen and O. BoermanArticles
CANBR
2004
457--465
Induction and myofibrillar targeting of CARP, and suppression of the Nkx2.5 pathway in the MDM mouse with impaired titin-based signaling
C. Witt, Y. Ono, E. Puschmann, M. McNabb, Y. Wu, M. Gotthardt, S. Witt, M. Haak, D. Labeit, C. Gregorio, H. Sorimachi, H. Granzier and S. LabeitArticles
JMOLBIOL
2004
145--154
Role of FDG-PET in the diagnosis and management of lung cancer
W. Oyen, J. Bussink, A. Verhagen, F. Corstens and G. BootsmaArticles
ERACT
2004
561--567
18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature
M. Gotthardt, A. Battmann, H. Höffken, T. Schurrat, H. Pollum, D. Beuter, S. Gratz, M. Béhé, A. Bauhofer, K. Klose and T. BehrArticles
NUCMC
2004
439--443
Development and clinical application of peptide-based radiopharmaceuticals
M. Gotthardt, O. Boermann, T. Behr, M. Béhé and W. OyenArticles
Curr Pharm Des
2004
2951--2963
Clinical value of parathyroid scintigraphy with technetium-99m methoxyisobutylisonitrile: discrepancies in clinical data and a systematic metaanalysis of the literature
M. Gotthardt, B. Lohmann, T. Behr, A. Bauhofer, C. Franzius, M. Schipper, M. Wagner, H. Höffken, H. Sitter, M. Rothmund, K. Joseph and C. NiesArticles
WJSURG
2004
100--107